Varenicline (trade name Chantix in the USA and Champix in Canada, Europe and other countries, marketed by Pfizer, usually in the form of varenicline tartrate), is a prescription medication used to treat smoking addiction. Varenicline is a nicotinic receptor partial agonist - it stimulates nicotine receptors more weakly than nicotine itself does. In this respect it is similar to cytisine and different from the nicotinic antagonist, bupropion, and nicotine replacement therapies (NRTs) like nicotine patches and nicotine gum. As a partial agonist it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. Through these mechanisms it can assist some patients to quit smoking.

Read more about VareniclineMedical Uses, Adverse Effects, Mechanism of Action, Pharmacokinetics, History

Other articles related to "varenicline":

Bupropion - Medical Uses - Smoking Cessation
... a single trial that compared bupropion and varenicline (Chantix) directly, varenicline showed superior efficacy after one year, the rate of continuous abstinence was 10% for placebo, 15% for ...
Smoking Cessation - Methods - Single Medications
... Varenicline tartrate is a prescription drug marketed by Pfizer as Chantix in the U.S ... Synthesized as an improvement upon cytisine, varenicline decreases the urge to smoke and reduces withdrawal symptoms ... funding from Pfizer, one in 2006 and one in 2009, found varenicline more effective than NRT or bupropion ...
Varenicline - History
... Varenicline was discovered at Pfizer through the research aimed at modifying the structure of cytisine ... Varenicline received a "priority review" by the U.S ... August 1, 2006, varenicline was made available for sale in the United States and on September 29, 2006, was approved for sale in the European Union ...